In addition to the Chief Executive Officer and Chief Operating Officer of PharmaCyte Biotech, the Consortium is made up of well-known scientists from leading Universities in Munich, Germany, Vienna, Austria, and Sydney, Australia. It also involves members of the Karolinska Institute in Stockholm, Sweden, the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) in Feldkirch, Austria and the biotech company Austrianova.
Dr. Brandtner of VIVIT, who is a consultant for PharmaCyte Biotech, previously served as the Chief Scientist with Austrianova. In that role, she conducted preclinical studies with Melligen cells – human cells engineered to produce, store and secrete insulin at levels that are in direct proportion to the levels of glucose (blood sugar) in the human body. PharmaCyte Biotech has obtained from the University of Sydney (UTS) in Australia an exclusive, worldwide license to use the Melligen cells in the development of PharmaCyte Biotech’s treatment for diabetes.
Prof. Ann. M Simpson and her colleagues at the UTS developed the Melligen cell line. Prof. Simpson is a member of the Consortium and also serves as a consultant to PharmaCyte Biotech. In addition to key personnel from PharmaCyte Biotech, Dr. Brandtner and Prof. Simpson, the Consortium includes principals from our partner Austrianova, namely Prof. Walter H. Gunzburg, the Chief Scientific Officer of PharmaCyte Biotech and the Chief Technical Officer of Austrianova, and Dr. Brian Salmons, the CEO of Austrianova and a member of the PharmaCyte Biotech Scientific Advisory Board. Prof. Gunzburg and Dr. Salmons are co-developers of the Cell-in-a-Box(R) technology. Also part of the Consortium is Dr. Constantine Konstantoulas from the University of Veterinary Medicine Vienna (VetMed) where many of the initial preclinical studies will be done to develop PharmaCyte Biotech’s diabetes treatment. The studies with the Melligen cells are already underway at VetMed and are being coordinated by Dr. Konstantoulas.
Other members of the Diabetes Consortium include the outstanding research scientists Prof. Eckhard Wolf and Prof. Rudiger Wanke from the Ludwig-Maximillian University in Munich, Germany. Both, together with their colleagues at that University, have developed unique animal models for insulin-dependent diabetes. Finally, noted European gastroenterologist and oncologist, Prof. Dr. Matthias Lohr of the renowned Karolinska Institute in Stockholm, Sweden, will play a major role in overseeing the development of PharmaCyte Biotech’s diabetes treatment. Prof. Dr. Lohr is an expert in the treatment of diabetes and has extensive experience in the clinic using the Cell-in-a-Box(R) technology because he served as Principal Investigator for the early-phase clinical trials that involved the combination of that technology and the cancer drug ifosfamide. Prof. Lohr is a consultant to PharmaCyte Biotech and serves as the Chairman of PharmaCyte Biotech’s Scientific Advisory Board.
Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte Biotech, said, “The latest meeting of our international Diabetes Consortium was extremely productive. We are extremely pleased that Dr. Brandtner has assumed a leadership role in the Consortium. Every member of the Consortium is united in the belief that encapsulated human cells that have been reprogrammed to respond to blood sugar levels in a human suffering from diabetes is the way forward to develop a unique and effective treatment for insulin-dependent diabetes. Our most recent meeting has resulted in the laser-focused planning of the steps required to be able to reach this goal. The preclinical studies are already underway, and every member of our international Diabetes Consortium is dedicated and focused on developing a novel and effective treatment for diabetes. We are very fortunate to have so many outstanding professionals working in concert to achieve this goal.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R). This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech’s treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or “cancer-killing” form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This “targeted chemotherapy” has proven remarkably effective in past clinical trials. PharmaCyte Biotech is also working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors. In addition, PharmaCyte Biotech is developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box(R) technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech the rare opportunity to develop “green” approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte’s ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyteBiotech.com. It can also be obtained by contacting Investor Relations.
Investor Relations Contacts: Jamien Jones Blueprint Life Science Group Telephone: 415.375.3340 Ext. 103 firstname.lastname@example.org
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | email@example.com